Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 5 of 5 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/30/21
End: 11/14/22
Due: 11/14/23
Phase: N/A
Priority: Normal
Start: 04/30/12
End: 07/31/13
Due: 07/31/14
Phase: N/A
Priority: Normal
Start: 06/09/22
End: 11/07/23
Due: 11/07/24
Phase: N/A
Priority: Normal
Start: 05/03/18
End: 03/09/21
Due: 03/09/22
Phase: N/A
Priority: Normal
Start: 10/25/21
End: 03/18/22
Due: 03/18/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose | NCT04715230 | InterveXion Therapeutics, LLC | user2@example.com | None | 2021-06-30 | 2022-11-14 | 2023-11-14 | - | - | 2025-07-14 |
| Safety Study of Ch-mAb7F9 for Methamphetamine Abuse | NCT01603147 | InterveXion Therapeutics, LLC | user2@example.com | None | 2012-04-30 | 2013-07-31 | 2014-07-31 | - | - | 2025-07-14 |
| Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200 | NCT05034874 | InterveXion Therapeutics, LLC | user2@example.com | None | 2022-06-09 | 2023-11-07 | 2024-11-07 | - | - | 2025-07-14 |
| Study of Antibody for Methamphetamine Outpatient Therapy | NCT03336866 | InterveXion Therapeutics, LLC | user2@example.com | None | 2018-05-03 | 2021-03-09 | 2022-03-09 | - | - | 2025-07-14 |
| Safety, Tolerability, and Pharmacokinetics of IXT-m200 | NCT05027451 | InterveXion Therapeutics, LLC | user2@example.com | None | 2021-10-25 | 2022-03-18 | 2023-03-18 | - | - | 2025-07-14 |